Stephens Inc. AR bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,747 shares of the medical equipment provider’s stock, valued at approximately $686,000.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. CWM LLC lifted its position in Lantheus by 82.1% in the third quarter. CWM LLC now owns 366 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 165 shares during the last quarter. Veriti Management LLC increased its position in shares of Lantheus by 5.4% during the third quarter. Veriti Management LLC now owns 3,270 shares of the medical equipment provider’s stock worth $230,000 after purchasing an additional 168 shares in the last quarter. Strs Ohio grew its stake in Lantheus by 1.4% during the 3rd quarter. Strs Ohio now owns 22,500 shares of the medical equipment provider’s stock worth $1,582,000 after buying an additional 300 shares during the last quarter. Bank of Montreal Can grew its stake in Lantheus by 1.7% during the 1st quarter. Bank of Montreal Can now owns 18,279 shares of the medical equipment provider’s stock worth $1,026,000 after buying an additional 303 shares during the last quarter. Finally, FinTrust Capital Advisors LLC purchased a new position in shares of Lantheus in the 2nd quarter valued at approximately $26,000. Institutional investors own 97.62% of the company’s stock.
Wall Street Analyst Weigh In
LNTH has been the subject of a number of research reports. Jonestrading assumed coverage on Lantheus in a research report on Thursday, October 6th. They set a “buy” rating and a $104.00 price target for the company. SVB Leerink began coverage on shares of Lantheus in a research note on Wednesday, November 30th. They issued an “outperform” rating on the stock. Mizuho began coverage on shares of Lantheus in a research note on Wednesday, October 12th. They set a “buy” rating and a $105.00 price target for the company. Finally, StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 4th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Lantheus has a consensus rating of “Buy” and a consensus target price of $102.80.
Lantheus Price Performance
Lantheus (NASDAQ:LNTH – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The medical equipment provider reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.15. The business had revenue of $239.29 million during the quarter, compared to analyst estimates of $228.52 million. Lantheus had a net margin of 13.35% and a return on equity of 37.77%. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 3.53 earnings per share for the current fiscal year.
Insider Activity at Lantheus
In related news, CEO Mary Anne Heino sold 13,150 shares of the firm’s stock in a transaction on Tuesday, November 8th. The shares were sold at an average price of $57.21, for a total transaction of $752,311.50. Following the completion of the transaction, the chief executive officer now directly owns 672,533 shares of the company’s stock, valued at $38,475,612.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Mary Anne Heino sold 13,150 shares of Lantheus stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $57.21, for a total transaction of $752,311.50. Following the completion of the sale, the chief executive officer now owns 672,533 shares in the company, valued at approximately $38,475,612.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Daniel Niedzwiecki sold 3,000 shares of the business’s stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $59.73, for a total transaction of $179,190.00. Following the completion of the sale, the insider now owns 65,143 shares of the company’s stock, valued at approximately $3,890,991.39. The disclosure for this sale can be found here. Insiders have sold a total of 19,354 shares of company stock worth $1,105,945 over the last quarter. Company insiders own 1.60% of the company’s stock.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.
- Get a free copy of the StockNews.com research report on Lantheus (LNTH)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.